Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Ann Oncol ; 24(2): 343-349, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23022995

ABSTRACT

BACKGROUND: Activation of the c-Met pathway occurs in a range of malignancies, including papillary renal cell carcinoma (RCC). Its activity in clear cell RCC is less clear. We investigated c-Met expression and inhibition in a large cohort of RCC tumors and cell lines. METHODS: c-Met protein expression was determined by automated quantitative analysis (AQUA) on a tissue microarray (TMA) constructed from 330 RCC tumors paired with adjacent normal renal tissue. c-Met expression and selective inhibition with SU11274 and ARQ 197 were studied in clear cell RCC cell lines. RESULTS: Higher c-Met expression was detected in all RCC subtypes than in the adjacent normal renal tissue (P < 0.0001). Expression was highest in papillary and sarcomatoid subtypes, and high-grade and stage tumors. Higher c-Met expression correlated with worse disease-specific survival [risk ratio = 1.36; 95% confidence interval (CI) 1.08-1.74; P = 0.0091] and was an independent predictor of survival, maintained in clear cell subset analyses. c-Met protein was activated in all cell lines, and proliferation (and colony formation) was blocked by SU11274 and ARQ 197. CONCLUSIONS: c-Met is associated with poor pathologic features and prognosis in RCC. c-Met inhibition demonstrates in vitro activity against clear cell RCC. Further study of ARQ 197 with appropriate biomarker studies in RCC is warranted.


Subject(s)
Carcinoma, Renal Cell/metabolism , Kidney Neoplasms/metabolism , Proto-Oncogene Proteins c-met/metabolism , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/metabolism , Carcinoma, Renal Cell/drug therapy , Cell Line, Tumor , Cell Proliferation , Female , Hepatocyte Growth Factor/antagonists & inhibitors , Hepatocyte Growth Factor/metabolism , Humans , Indoles/pharmacology , Kidney Neoplasms/drug therapy , Male , Middle Aged , Piperazines/pharmacology , Prognosis , Pyrrolidinones/pharmacology , Pyrrolidinones/therapeutic use , Quinolines/pharmacology , Quinolines/therapeutic use , Sulfonamides/pharmacology , Tissue Array Analysis
2.
Regul Pept ; 162(1-3): 52-60, 2010 Jun 08.
Article in English | MEDLINE | ID: mdl-20144901

ABSTRACT

YF476 is a potent and highly selective cholecystokin 2 (CCK(2)) receptor antagonist of the benzodiazepine class. It inhibits gastric neuroendocrine enterochromaffin-like (ECL) cell secretion, proliferation and spontaneous formation of gastric neuroendocrine tumors (carcinoids) in cotton rats. The Mastomys rodent species exhibits a genetic predisposition to gastric ECL neuroendocrine tumor formation which can be accelerated by acid suppression and induction of hypergastrinemia. In this respect, it mimics the human condition of atrophic gastritis, hypergastrinemia and gastric carcinoid development. We investigated whether YF476 could inhibit acid suppression-induced ECL cell hyperplasia and neoplasia in this model. In addition, we examined whether YF476 could reverse established ECL cell hyperplasia and neoplasia. Targeting the CCK(2) receptor during Loxtidine-induced hypergastrinemia resulted in a reduction in ECL cell secretion (plasma and mucosal histamine, and histidine decarboxylase (HDC) transcripts, p<0.05) and proliferation (numbers of HDC-positive cells, connective tissue growth factor (CTGF) and cyclin D1 transcription). This was associated with a decrease in ECL cell hyperplasia and a 60% reduction in gastric ECL cell microcarcinoid (tumors <0.3mm in size) formation. YF476 inhibited ECL cell neoplasia (gastric carcinoid) in animals with hyperplasia, inhibited the formation of ECL cell tumors when co-administered with Loxtidine and reversed the growth and developement of gastric ECL cell carcinoids in long-term acid suppressed Mastomys. Variable importance analysis using a logistic multinomial regression model indicated the effects of YF476 were specific to the ECL cell and alterations in ECL cell function reflected inhibition of transcripts for HDC, Chromogranin A (CgA), CCK(2) and the autocrine growth factor, CTGF. We conclude that specifically targeting the CCK(2) receptor inhibits gastrin-mediated ECL cell secretion and ECL cell proliferation and tumor development in vivo.


Subject(s)
Benzodiazepinones/pharmacology , Hyperplasia/prevention & control , Phenylurea Compounds/pharmacology , Receptor, Cholecystokinin B/antagonists & inhibitors , Stomach Neoplasms/prevention & control , Animals , Enzyme-Linked Immunosorbent Assay , Female , Male , Murinae , Polymerase Chain Reaction , Serotonin/metabolism , Stomach Neoplasms/pathology
3.
Ann Oncol ; 21(3): 466-473, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19717535

ABSTRACT

BACKGROUND: Growth factor receptor-bound protein-7 (Grb7) is an adapter-type signaling protein recruited to various tyrosine kinases, including HER2/neu. Grb7-specific inhibitors are in early development. As with other targeted therapies, response to therapy might be associated with target expression. MATERIALS AND METHODS: Tissue microarrays containing 638 primary breast cancer specimens with 15-year patient follow-up were employed to assess Grb7 expression using our Automated QUantitative Analysis method; cytokeratin defines pixels as breast cancer (tumor mask) within the histospot, and Grb7 expression within the mask is measured with Cy5-conjugated antibodies. RESULTS: High Grb7 expression was strongly associated with decreased survival in the entire cohort and in the node-positive subset (P = 0.0034 and P = 0.0019, respectively). On multivariable analysis, it remained an independent prognostic marker (P = 0.01). High Grb7 was strongly associated with high HER2/neu, and coexpression of these molecules was associated with worse prognosis than HER2/neu overexpression alone. CONCLUSIONS: High Grb7 defines a subset of breast cancer patients with decreased survival, indicating that Grb7 might be a valuable prognostic marker and drug target. Coexpression with HER2/neu indicates that cotargeting these molecules might be an effective approach for treating HER2/neu-positive breast cancers. Future studies using Grb7-targeting agents should include assessment of Grb7 levels.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Lobular/metabolism , GRB7 Adaptor Protein/metabolism , Adult , Aged , Aged, 80 and over , Blotting, Western , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , Female , Fluorescent Antibody Technique , Follow-Up Studies , Humans , Image Processing, Computer-Assisted , Middle Aged , Prognosis , Receptor, ErbB-2/metabolism , Survival Rate , Tissue Array Analysis , Tumor Cells, Cultured , Young Adult
4.
Hum Pathol ; 40(2): 156-65, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18799189

ABSTRACT

Microvessel density may be one measure of tumor associated angiogenesis but is methodologically difficult to standardize and reproduce. We used our automated quantitative image analysis system, AQUA, to more objectively assess microvessel area. Cytokeratin and CD31 were used to create tumor and vessel compartments respectively with AQUA. Microvessel area was defined as CD31 compartment area normalized to the tissue spot area (CD31 area/area of entire tissue spot). Consecutive breast cancer whole sections were stained with CD31 to compare pathologist-based microvessel density with AQUA microvessel area. Microvessel areas of 3-fold redundant tissue microarrays of 652 primary breast cancers were also assessed. CD34 and factor VIII-related antigen were also tested. There was nearly linear correlation between pathologist's microvessel density and AQUA microvessel area with regression coefficient R = 0.846. On the redundant arrays, of the 67% evaluable cases, 52% were microvessel area high and 48% low with good reproducibility of scores (Spearman rho 0.551). AQUA microvessel area was associated with larger tumors, node positivity, and estrogen receptor negativity, with 20 year survival at the univariate and multivariate levels (P < .0001 and P = .0121, respectively). CD34 or factor VIII-related antigen were more heterogenous, had poor association with CD31, and did not correlate with outcome. AQUA-based microvessel area was significantly correlated with both standard breast cancer prognostic parameters as well as with clinical outcome. In the future, it may also allow the use of the AQUA-based algorithms to quantify the expression of angiogenic biomarkers to either tumor or microvessel area-specific compartments.


Subject(s)
Breast Neoplasms/blood supply , Breast Neoplasms/pathology , Image Processing, Computer-Assisted/methods , Microvessels/pathology , Neovascularization, Pathologic/pathology , Automation , Breast Neoplasms/metabolism , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Microvessels/metabolism , Middle Aged , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Prognosis , Reproducibility of Results , Tissue Array Analysis
5.
Ann Oncol ; 19(3): 590-4, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18037622

ABSTRACT

BACKGROUND: HSP90 chaperones molecules critical for cell survival and malignant progression, including mutated B-raf. HSP90-targeting agents are in clinical trials. No large studies have been conducted on expression of HSP90 in melanomas. MATERIALS AND METHODS: Tissue microarrays containing 414 nevi, 198 primary and 270 metastatic melanomas were assessed using our automated quantitative analysis (AQUA) method of in situ protein measurement; we use S-100 to define pixels as melanocytes (tumor mask) within the array spot, and measure HSP90 expression within the mask using Cy5-conjugated antibodies. RESULTS: HSP90 expression was higher in melanomas than nevi (P < 0.0001) and higher in metastatic than primary specimens (P < 0.0001). No association was seen between high HSP90 expression and survival in the primary or metastatic patient subsets. In primary melanomas, high HSP90 expression was associated with higher Clark level (P = 0.0167) and increased Breslow depth (P < 0.0001). CONCLUSIONS: HSP90 expression was significantly higher in tumors than nevi and was associated with disease progression, indicating that it might be a valuable drug target in melanoma, as well as a useful diagnostic marker. Prospective studies are needed to confirm the diagnostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors.


Subject(s)
Biomarkers, Tumor/analysis , HSP90 Heat-Shock Proteins/analysis , Melanoma/chemistry , Skin Neoplasms/chemistry , Algorithms , Animals , Blotting, Western , CHO Cells , Cell Line, Tumor , Cricetinae , Cricetulus , Disease Progression , Humans , Immunohistochemistry , Melanoma/pathology , Melanoma/secondary , Skin Neoplasms/pathology
6.
World J Gastroenterol ; 13(39): 5208-16, 2007 Oct 21.
Article in English | MEDLINE | ID: mdl-17876891

ABSTRACT

AIM: To investigate the role of small intestinal carcinoid tumor-derived fibrotic mediators, TGFbeta1 and CTGF, in the mediation of fibrosis via activation of an "intestinal" stellate cell. METHODS: GI carcinoid tumors were collected for Q RT-PCR analysis of CTGF and TGFbeta1. Markers of stellate cell desmoplasia were identified in peritoneal fibrosis by immunohistochemistry and stellate cells cultured from fresh resected fibrotic tissue. CTGF and TGFbeta1 were evaluated using quantitative tissue array profiling (AQUA analysis) in a GI carcinoid tissue microarray (TMA) with immunostaining and correlated with clinical and histologically documented fibrosis. Serum CTGF was analyzed using a sandwich ELISA assay. RESULTS: Message levels of both CTGF and TGFbeta1 in SI carcinoid tumors were significantly increased (> 2-fold, P < 0.05) versus normal mucosa and gastric (non-fibrotic) carcinoids. Activated stellate cells and markers of stellate cell-mediated fibrosis (vimentin, desmin) were identified in histological fibrosis. An intestinal stellate cell was immunocytochemically and biochemically characterized and its TGFbeta1 (10-7M) initiated CTGF transcription response (> 3-fold, P < 0.05) demonstrated. In SI carcinoid tumor patients with documented fibrosis, TMA analysis demonstrated higher CTGF immunostaining (AQUA Score: 92 +/- 8; P < 0.05), as well as elevated TGFbeta1 (90.6 +/- 4.4, P < 0.05). Plasma CTGF (normal 12.5 +/- 2.6 ng/mL) was increased in SI carcinoid tumor patients (31 +/- 10 ng/mL, P < 0.05) compared to non-fibrotic GI carcinoids (< 15 ng/mL). CONCLUSION: SI carcinoid tumor fibrosis is a CTGF/TGFbeta1-mediated stellate cell-driven fibrotic response. The delineation of the biology of fibrosis will facilitate diagnosis and enable development of agents to obviate its local and systemic complications.


Subject(s)
Carcinoid Tumor/etiology , Carcinoid Tumor/metabolism , Gastrointestinal Neoplasms/etiology , Gastrointestinal Neoplasms/metabolism , Immediate-Early Proteins/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Intestine, Small/metabolism , Adult , Aged , Carcinoid Tumor/pathology , Case-Control Studies , Cells, Cultured , Connective Tissue Growth Factor , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Female , Fibrosis/etiology , Fibrosis/metabolism , Fibrosis/pathology , Gastrointestinal Neoplasms/pathology , Humans , Intestine, Small/pathology , Male , Middle Aged , RNA, Messenger/metabolism , Tissue Array Analysis , Transforming Growth Factor beta1/metabolism
7.
Ann Oncol ; 18(4): 709-15, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17220511

ABSTRACT

BACKGROUND: p53 protein is regarded as a valuable prognostic marker in cancer with a potential use as a molecular target. Here, we sought to determine the prognostic value of p53 in ovarian cancer using a novel method of compartmentalized in situ protein analysis. PATIENTS AND METHODS: A tissue array composed of 141 advanced stage ovarian cancers uniformly treated was constructed. For evaluation of p53 protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA). RESULTS: High nuclear p53 expression levels were associated with better outcome for overall survival (OS) (P = 0.0023) and disease-free survival (P = 0.0338) at 5-years. High cytoplasmic p53 expression levels were associated with better outcome for OS (P = 0.0002). In multivariable analysis, high nuclear and high cytoplasmic p53 level with International Federation of Gynecology and Obstetrics (FIGO) stage were the most significant predictor variables for OS and high nuclear p53 level with FIGO stage were the significant predictor variables for disease-free survival. CONCLUSIONS: Assessment of the prognostic value of p53 protein levels using conventional immunohistochemistry is limited by the nonquantitative nature of the method. AQUA provides precise estimation of p53 protein levels and was able to elucidate the association of p53 protein levels and ovarian cancer prognosis.


Subject(s)
Ovarian Neoplasms/chemistry , Tissue Array Analysis/methods , Tumor Suppressor Protein p53/analysis , Adult , Aged , Female , Genes, p53 , Humans , Middle Aged , Mutation , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis
8.
Am J Physiol Gastrointest Liver Physiol ; 292(1): G191-200, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16950763

ABSTRACT

Mastomys enterochromaffin-like (ECL) cell proliferation is initially gastrin driven, but once neoplasia develops, cells become gastrin autonomous. We hypothesized that CCN2 (CTGF), a mitogenic growth factor, may regulate ECL cell proliferation. A Mastomys GeneChip database was examined (dCHIP) to identify CCN2 expression levels. CCN2 in normal and tumor ECL cell preparations obtained using FACS (100 nM acridine orange) was examined by real-time PCR. CCN2 protein was identified in mucosal and ECL cell preparations by immunohistochemistry. Short-term cultured cells were stimulated with either CCN2 or CCN2 + EGF, and proliferation was measured (MTT assay). The ERK1/2 inhibitor PD-98059 (0.1-100 microM) was assessed in terms of CCN2 (1 ng/ml)-mediated proliferation and ERK1/2 phosphorylation. CCN2 transcript and protein was then examined in clinical gastric carcinoids. The ccn2 transcript was upregulated in tumor samples compared with the normal mucosa (+2.36-fold, P < 0.01). PCR demonstrated that ccn2 was not expressed in FACS-prepared (>98% pure) normal ECL cells but was elevated in tumor ECL cell fractions (41.3 +/- 10.7-fold). Immunostaining of the Mastomys gastric mucosa and FACS preparations confirmed that CCN2 protein was present in ECL tumors but not in normal ECL cells. Neither CCN2 nor CCN2 + EGF stimulated normal ECL cell proliferation. CCN2 stimulated tumor proliferation (EC50 approximately 0.01 ng/ml); EGF significantly augmented (P < 0.01) CCN2-induced tumor cell proliferation (EC50 = 20 pg/ml). PD-98059 inhibited CCN2-induced proliferation (-12 +/- 3%, P < 0.05) and ERK1/2 phosphorylation (-34 +/- 5%, P < 0.05) in tumor cells. In clinical samples, both CCN2 transcript and protein were elevated in gastrin-autonomous carcinoids (P < 0.02) compared with the normal mucosa. In conclusion, CCN2 may be a proliferative regulator of Mastomys ECL neoplastic proliferation once these cells become autonomous of gastrin regulation. Identification of CCN2 in gastric carcinoid tissue may be useful both as an indicator of ECL cell transformation and may define gastrin autonomy, a criteria of gastric carcinoid malignancy.


Subject(s)
Carcinoid Tumor/pathology , Enterochromaffin Cells/cytology , Immediate-Early Proteins/physiology , Intercellular Signaling Peptides and Proteins/physiology , Stomach Neoplasms/pathology , Animals , Cell Division , Connective Tissue Growth Factor , Enterochromaffin Cells/pathology , Gastric Mucosa/physiology , Hyperplasia , Immediate-Early Proteins/genetics , Intercellular Signaling Peptides and Proteins/genetics , Murinae , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction
9.
Ann Oncol ; 17(12): 1797-802, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16971669

ABSTRACT

BACKGROUND: The deleted in colorectal cancer (DCC) protein, the product of DCC tumor suppressor gene, is frequently altered in cancer. Preclinical data demonstrate that DCC regulates beta-catenin levels. Here, we sought to determine the association of DCC with beta-catenin protein levels, clinicopathological parameters and patient outcome in ovarian cancer using a method of in situ compartmentalized protein analysis. METHODS: A tissue array composed of 150 advanced-stage ovarian cancers, treated with surgical debulking and platinum-paclitaxel (Taxol) combination chemotherapy, was constructed. For evaluation of protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA). RESULTS: One hundred and twelve patients (74%) had sufficient tissue for AQUA. The median follow-up time for the entire cohort was 33 months. Patients with low nuclear DCC expression had a 3-year progression-free survival (PFS) rate of 0% compared with 33% of those with high DCC expression (P = 0.0067). In multivariate analysis, low nuclear DCC expression level retained its prognostic significance for PFS. Between DCC and beta-catenin, a significant relationship was found, where tumors with low DCC had low beta-catenin and vice versa (P = 0.003). CONCLUSIONS: Low nuclear DCC levels predict for poor patient outcome in epithelial ovarian cancer. DCC may exert its antitumor function, in part, through regulation of beta-catenin levels.


Subject(s)
Genes, DCC , Neoplasms, Glandular and Epithelial/metabolism , Ovarian Neoplasms/metabolism , beta Catenin/metabolism , Automation , Cohort Studies , Female , Fluorescent Antibody Technique , Humans , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/pathology , Survival Analysis , Tissue Array Analysis
10.
Clin Cancer Res ; 11(7): 2471-7, 2005 Apr 01.
Article in English | MEDLINE | ID: mdl-15814622

ABSTRACT

BACKGROUND: beta-catenin, depending on subcellular localization, plays a dual role in carcinogenesis: as a signaling factor (in the nucleus) and as an adhesion molecule (in cell membrane). In this study, we sought to determine the role of beta-catenin in head and neck carcinogenesis. METHODS: First, we studied the incidence of mutations of beta-catenin in a cohort of 60 head and neck squamous cell cancers (HNSCC). We subsequently evaluated the protein expression levels of beta-catenin in a cohort of oropharyngeal squamous cell cancer tissue microarray using a novel in situ method of quantitative protein analysis and correlated those with cyclin D1 levels and clinical and pathologic data. RESULTS: The mean follow-up time for survivors was 45 months and for all patients was 35 months. We found no mutations in the cohort of 60 HNSCC. beta-catenin displayed primarily membranous expression pattern. Patients with high tumor-node-metastasis stage were more likely to have high expression of beta-catenin (P = 0.040). Patients with low beta-catenin expression had a local recurrence rate of 79% compared with 29% for patients with high beta-catenin tumors (P = 0.0021). Univariate Cox regression revealed a hazard ratio for low beta-catenin tumors of 3.6 (P = 0.004). Kaplan-Meier analysis showed that patients with low beta-catenin expressing tumors trended toward worse 5-year disease-free survival (P = 0.06). In multivariate analysis, only beta-catenin expression status was an independent prognostic factor (P = 0.044) for local recurrence. Tumors with high beta-catenin had low cyclin D1 and vice versa (P = 0.007). CONCLUSIONS: The absence of activating beta-catenin mutations combined with the inverse correlation between beta-catenin levels with cyclin D1 levels and outcome suggest that beta-catenin mainly functions as an adhesion and not signaling molecule in HNSCC.


Subject(s)
Carcinoma, Squamous Cell/pathology , Cell Adhesion Molecules/physiology , Cytoskeletal Proteins/genetics , Head and Neck Neoplasms/pathology , Trans-Activators/genetics , Adult , Aged , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cyclin D1/analysis , Cytoskeletal Proteins/analysis , Cytoskeletal Proteins/physiology , DNA Mutational Analysis , Female , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Humans , Immunohistochemistry/methods , Male , Middle Aged , Multivariate Analysis , Mutation , Neoplasm Staging , Survival Analysis , Trans-Activators/analysis , Trans-Activators/physiology , beta Catenin
11.
Exp Mol Pathol ; 70(3): 255-64, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11418004

ABSTRACT

Tissue microarrays are a method of relocating tissue from conventional histologic paraffin blocks in a manner that tissue from multiple patients or blocks can be seen on the same slide. This is done by using a needle to biopsy a standard histologic section and placing the core into an array on a recipient paraffin block. This technique allows maximization of tissue resources by analysis of small core biopsies of blocks, rather than complete sections. Using this technology, a carefully planned array can be constructed using cases from pathology tissue block archives, and a 20-year survival analysis can be done on a cohort of 600 or more patients using only a few microliters of antibody in a single experiment. Furthermore, this cohort can be analyzed thousands of times with different reagents as a result of judicious sectioning of the array block. This review describes this process and discusses the issues of representative sampling in heterogeneous lesions, the issue of antigen preservation, and some technical strategies and methods of array construction. In summary, this technique can provide a highly efficient, high-throughput mechanism for evaluation of protein expression in large cohorts. It has the potential for allowing validation of new genes at a speed comparable to the rapid rate of gene discovery afforded by DNA microarrays.


Subject(s)
Histological Techniques/methods , Neoplasms/genetics , Neoplasms/pathology , Pathology/methods , Histological Techniques/instrumentation , Humans , Oligonucleotide Array Sequence Analysis , Pathology/instrumentation
12.
Cancer J ; 7(1): 24-31, 2001.
Article in English | MEDLINE | ID: mdl-11269645

ABSTRACT

Tissue microarrays are a method of harvesting small disks of tissue from a range of standard histologic sections and placing them in an array on a recipient paraffin block such that hundreds of cases can be analyzed simultaneously. This technique allows maximization of tissue resources by analysis of small-core biop sies of blocks, rather than complete sections. Using this technology, a carefully planned array can be constructed with cases from pathology tissue block archives, such that a 20-year survival analysis can be performed on a cohort of 600 or more patients by use of only a few microliters of antibody in a single experiment. The reflex criticism of this technique is that the tissue analyzed is not representative, especially in antigens with heterogeneous staining patterns. This review addresses this issue, as well as the issue of antigen preservation or durability, which validates construction of arrays from archives. Strategies and methods of construction and analysis of the arrays are discussed, as well as some other unusual array applications. This technique can provide a highly efficient, high-throughput mechanism for evaluation of protein expression in large cohorts. It has the potential to allow validation of new genes at a speed comparable to the rapid rate of gene discovery afforded by DNA microarrays.


Subject(s)
Gene Expression Profiling/methods , Histocytological Preparation Techniques/methods , Neoplasms/pathology , Precancerous Conditions/pathology , Sequence Analysis/methods , Antigens/analysis , Blood Cells/pathology , Fluorescent Antibody Technique/methods , Humans , Immunoenzyme Techniques , Neoplasms/chemistry
13.
Am J Pathol ; 158(3): 987-96, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11238046

ABSTRACT

beta-catenin has a role in cell adhesion and Wnt signaling. It is mutated or otherwise dysregulated in a variety of human cancers. In this study we assess beta-catenin alteration in 145 thyroid tumors samples from 127 patients. beta-catenin was localized using immunofluorescence and mutational analysis was performed by single-strand conformational polymorphism. Membrane beta-catenin expression was decreased in eight of 12 (66%) adenomas and in all 115 carcinomas (P: < 0.0001). Among carcinomas, reduced membrane beta-catenin was associated with progressive loss of tumor differentiation (P: < 0.0001). CTNNB1 exon 3 mutations and nuclear beta-catenin localization were restricted to poorly differentiated [7 of 28 (25%) and 6 of 28 cases (21.4%), respectively] or undifferentiated carcinomas [19 of 29 (65.5%) and 14 of 29 (48.3%) cases, respectively]. Poorly differentiated tumors always featured mutations involving Ser and Thr residues and were characterized by Thr to Ile amino acid substitutions (P: = 0.0283). The association between CTNNB1 exon 3 mutations and aberrant nuclear immunoreactivity (P: = 0.0020) is consistent with Wnt activation because of stabilizing beta-catenin mutations. Low membrane beta-catenin expression as well as its nuclear localization or CTNNB1 exon 3 mutations are significantly associated with poor prognosis, independent of conventional prognostic indicators for thyroid cancer but not of tumor differentiation. Analysis of beta-catenin dysregulation may be useful to objectively subtype thyroid neoplasms and more accurately predict outcomes.


Subject(s)
Adenoma/genetics , Biomarkers, Tumor/genetics , Carcinoma/genetics , Cytoskeletal Proteins/genetics , Thyroid Neoplasms/genetics , Trans-Activators , Adenoma/metabolism , Adenoma/mortality , Adenoma/pathology , Adult , Aged , Biomarkers, Tumor/metabolism , Carcinoma/metabolism , Carcinoma/mortality , Carcinoma/pathology , Cell Division , Cell Nucleus/metabolism , Cytoskeletal Proteins/metabolism , Down-Regulation , Exons , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Oncogene Protein p21(ras)/genetics , Phenotype , Point Mutation , Polymorphism, Single-Stranded Conformational , Prognosis , Survival Rate , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/mortality , Thyroid Neoplasms/pathology , beta Catenin
14.
Spine (Phila Pa 1976) ; 25(12): 1589-92, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10851111

ABSTRACT

STUDY DESIGN: A report of two cases of aneurysmal bone cysts of the spine occurring in a father and daughter. OBJECTIVE: To present an unusual finding of familial incidence of aneurysmal bone cyst and review the literature. SUMMARY OF BACKGROUND DATA: Aneurysmal bone cysts are benign, expanding, locally aggressive lesions. Up to 20% of cases involve the spine. The cause of primary aneurysmal bone cysts remains unclear. There have been three previous reports of a familial incidence supporting the importance of a hereditary component in the cause of aneurysmal bone cysts. METHODS: A 36-year-old man and a 7-year-old girl were diagnosed with aneurysmal bone cyst involving the spine by clinical manifestations, radiographic features, and histologic evaluation. RESULTS: The father remains recurrence- and symptom-free 6 years after primary resection. Five months after surgery, the daughter was found to have recurrent disease by magnetic resonance imaging and underwent a second procedure within 1 year of the primary resection. CONCLUSION: The occurrence of a primary aneurysmal bone cyst in two family members, occurring at adjacent vertebral levels, is suggestive of a hereditary component to the formation of primary aneurysmal bone cyst.


Subject(s)
Bone Cysts, Aneurysmal/genetics , Family Health , Spinal Diseases/genetics , Adult , Bone Cysts, Aneurysmal/diagnostic imaging , Bone Cysts, Aneurysmal/surgery , Child , Female , Humans , Magnetic Resonance Imaging , Male , Spinal Diseases/diagnostic imaging , Spinal Diseases/surgery , Tomography, X-Ray Computed
15.
Cancer ; 88(1): 108-13, 2000 Jan 01.
Article in English | MEDLINE | ID: mdl-10618612

ABSTRACT

BACKGROUND: Lymph node metastasis is the oldest and most reliable prognostic indicator in breast carcinoma. In the absence of tumor metastasis, draining lymph nodes can undergo hyperplasia, resulting in increases in the number and size of detectable lymph nodes. The prognostic value of this process has never been established. Lymph node negative breast carcinoma provides a unique opportunity to study the downstream effects of increased lymphatic drainage and lymph node hyperplasia. METHODS: The authors studied 290 cases of lymph node negative breast carcinoma and provided patients with a median of 103 months of follow-up. The number of tumor free lymph nodes in ipsilateral axillary resections, as well as 10 traditional histopathologic markers, were analyzed for their prognostic value. RESULTS: The cohort was divided into quartiles according to the number of tumor negative lymph nodes. The 5-year survival for patients with 20 or more tumor free lymph nodes (top quartile) was 84.7%, compared with 96.3% for patients with fewer than 20 tumor free lymph nodes. The 5-year relative risk of dying of metastatic disease in the top quartile was 3.61 (95% confidence interval, 1.37-9.52, P = 0.01), independent of necrosis, tumor size, patient age, nuclear and histologic grade, lymphocytic infiltrate, and lymphovascular invasion. The absolute lymph node number was highly associated with the presence of necrosis in invasive tumor. CONCLUSIONS: The number of tumor free lymph nodes is a novel, independent predictor of aggressive disease in cases of lymph node negative breast carcinoma. This finding may be a biologic function of host-derived, and possibly tumor-derived, lymphangiogenic cytokines.


Subject(s)
Breast Neoplasms/pathology , Lymph Nodes/pathology , Adult , Aged , Aged, 80 and over , Analysis of Variance , Breast Neoplasms/surgery , Chi-Square Distribution , Female , Humans , Hyperplasia , Lymph Node Excision , Lymph Nodes/surgery , Lymphatic Metastasis , Middle Aged , Necrosis , Neoplasm Invasiveness , Predictive Value of Tests , Prognosis , Risk , Survival Analysis
16.
Lab Invest ; 80(12): 1943-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11140706

ABSTRACT

The recent development of tissue microarray technology has potentiated large-scale retrospective cohort studies using archival formalin-fixed, paraffin-embedded tissues. A major obstacle to broad acceptance of microarrays is that they reduce the amount of tissue analyzed from a whole tissue section to a disk, 0.6 mm in diameter, that may not be representative of the protein expression patterns of the entire tumor. In this study, we examine the number to disks required to adequately represent the expression of three common antigens in invasive breast carcinoma--estrogen receptor, progesterone receptor, and the Her2/neu oncogene--in 38 cases of invasive breast carcinoma. We compared the staining of 2 to 10 microarray disks and the whole tissue sections from which they were derived and determined that analysis of two disks is comparable to analysis of a whole tissue section in more than 95% of cases. To evaluate the potential for using archival tissue in such arrays, we created a breast cancer microarray of 8 to 11 cases from each decade beginning in 1932 to the present day and evaluated the antigenicity of these markers and others. This array demonstrates that many proteins retain their antigenicity for more than 60 years, thus validating their study on archival tissues. We conclude that the tissue microarray technique, with 2-fold redundancy, is a valuable and accurate method for analysis of protein expression in large archival cohorts.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/pathology , Cell Nucleus/pathology , Cohort Studies , Female , Humans , Neoplasm Invasiveness , Receptor, ErbB-2/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Reproducibility of Results , Retrospective Studies
17.
Cancer ; 86(11): 2259-65, 1999 Dec 01.
Article in English | MEDLINE | ID: mdl-10590366

ABSTRACT

BACKGROUND: Activation of Met, the receptor for scatter factor/hepatocyte growth factor, is associated with mitogenesis, motogenesis, and decreased cell adhesion. Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid. The authors previously demonstrated that Met expression is an independent prognostic marker associated with decreased survival in patients with breast carcinoma. METHODS: Expression of Met in 113 archival breast carcinoma specimens from patients with axillary lymph node negative invasive ductal carcinoma was evaluated using a standard immunoperoxidase technique. Cases were scored by two pathologists using an H-score algorithm and then analyzed for correlation with known prognostic factors and survival. RESULTS: Expression of Met showed a bimodal distribution with 25% of cases showing high levels of expression. In contrast to previous studies, the results of the current study showed a significant association between Met expression and nuclear and histologic grade. The 5-year survival rate for Met negative patients with tumors with low Met expression was 95% in this cohort, compared with 80% for patients with tumors showing high Met expression. Patients whose tumors had a high level of Met expression were found to have a 5-year relative risk (RR) of dying of metastatic disease of 5.05 (P = 0.03) independent of patient age and tumor size. Combined analysis of Met and nuclear grade resulted in a marked increase in independent predictive value (RR = 33.4; P < 0.01). CONCLUSIONS: The results of the current study found that high levels of Met expression were associated with death due to metastatic disease in patients with axillary lymph node negative breast carcinoma. Expression of Met may be a useful prognostic indicator of more aggressive disease in patients whose prognosis is not easily stratified by current histopathologic markers.


Subject(s)
Breast Neoplasms/genetics , Carcinoma/genetics , Gene Expression Regulation, Neoplastic , Lymph Nodes/pathology , Proto-Oncogene Proteins c-met/biosynthesis , Adult , Aged , Aged, 80 and over , Axilla , Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Carcinoma/pathology , Female , Hepatocyte Growth Factor/biosynthesis , Humans , Immunohistochemistry , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Prognosis
18.
J Immunol ; 156(5): 1804-9, 1996 Mar 01.
Article in English | MEDLINE | ID: mdl-8596030

ABSTRACT

We have investigated whether hapten-specific unresponsiveness could be induced if the interaction between LFA-1 (CD11a/CD18) and intercellular adhesion molecule-1 (CD54) was disrupted by blocking mAbs given to mice during sensitization with 2,4-dinitro-1-fluorobenzene. An extended period of more than 11 days between the last i.p. injection of mAb and challenge was chosen to ensure that the mAb did not persist in the animals at the time of hapten challenge, as analyzed by flow cytometry and immunohistochemistry. The contact sensitivity response was significantly reduced (p < 0.001) when a combination of mAb FD441.8 against LFA-1 and mAb YNI/1.7.4 against intercellular adhesion molecule-1 was given during the sensitization phase compared with normal rat IgG-treated control animals. Furthermore, the animals were resistant to resensitization to the same hapten. This hyporesponsiveness was hapten specific, since the contact sensitivity reaction of mAb-treated mice to oxazolone was the same as that of normal rat IgG-treated control animals. Together these data indicate that inhibition of LFA-1/intercellular adhesion molecule-1 mediated interactions between APCs and T cells during sensitization induced long term, Ag-specific, hyporesponsiveness of mice to the hapten 2,4-dinitro-1-fluoro-benzene.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Dinitrofluorobenzene/immunology , Immune Tolerance , Intercellular Adhesion Molecule-1/immunology , Lymphocyte Function-Associated Antigen-1/immunology , Animals , Binding, Competitive/immunology , Cell Movement/immunology , Dermatitis, Allergic Contact/pathology , Dermatitis, Allergic Contact/prevention & control , Drug Combinations , Female , Haptens/immunology , Hypersensitivity, Delayed/pathology , Immunity, Innate , Immunization , Mice , Mice, Inbred BALB C
19.
J Exp Med ; 181(1): 55-62, 1995 Jan 01.
Article in English | MEDLINE | ID: mdl-7528778

ABSTRACT

CD44 is a cell surface adhesion molecule that plays a role in leukocyte extravasation, leukopoiesis, T lymphocyte activation, and tumor metastasis. The principal known ligand for CD44 is the glycosaminoglycan hyaluronate, (HA), a major constituent of extracellular matrices. CD44 expression is required but is not sufficient to confer cellular adhesion to HA, suggesting that the adhesion function of the receptor is regulated. We recently demonstrated that CD44 in primary leukocytes is phosphorylated in a cell type- and activation state-dependent fashion. In this study we demonstrate that serines 325 and 327 within the cytoplasmic domain of CD44 are required for the constitutive phosphorylation of CD44 in T cells. Furthermore, we demonstrate that cells expressing mutated CD44 containing a serine to glycine substitution at position 325 or a serine to alanine substitution at amino acid 327 are defective in HA binding, CD44-mediated adhesion of T cells to smooth muscle cells, as well as ligand-induced receptor modulation. The effect of these mutations can be partially reversed by a monoclonal anti-CD44 antibody that enhances CD44-mediated HA binding.


Subject(s)
Carrier Proteins/metabolism , Hyaluronic Acid/metabolism , Receptors, Cell Surface/metabolism , Receptors, Lymphocyte Homing/metabolism , T-Lymphocytes/metabolism , Amino Acid Sequence , Animals , Antigenic Modulation , Base Sequence , Cell Adhesion , Endocytosis , Hyaluronan Receptors , Mice , Molecular Sequence Data , Mutagenesis, Site-Directed , Phosphorylation , Phosphoserine/metabolism , Structure-Activity Relationship
20.
J Exp Med ; 178(2): 497-507, 1993 Aug 01.
Article in English | MEDLINE | ID: mdl-8340756

ABSTRACT

The in vivo administration of certain monoclonal antibodies (mAbs) against the adhesion receptor, CD44, into normal mice induces both a modulation of CD44 from the surface of peripheral lymphocytes, and a concomitant increase in the amount of soluble CD44 in the serum. CD44-negative lymphocytes isolated from anti-CD44-treated mice exhibit normal homing patterns upon adoptive transfer, and are capable of reexpressing CD44 upon activation. The treatment of haptensensitized mice with anti-CD44 mAb inhibits their ability to mount a cutaneous delayed-type hypersensitivity (DTH) response within the first 24 h after hapten challenge. This inhibition reflects a block in both the edema and leukocyte infiltration of the cutaneous site of DTH, whereas the extravasation and accumulation of leukocytes in the draining lymph nodes progress normally. After 72 h, the leukocytes that extravasate into the site of antigen challenge express CD44. These results indicate that CD44 is not necessary for normal leukocyte circulation but is required for leukocyte extravasation into an inflammatory site involving nonlymphoid tissue.


Subject(s)
Hypersensitivity, Delayed/immunology , Lymphocytes/immunology , Receptors, Lymphocyte Homing/physiology , Animals , Antibodies, Monoclonal/immunology , Cell Membrane/immunology , Female , Haptens/immunology , Humans , Immunotherapy, Adoptive , Lymphocyte Activation , Lymphoid Tissue/cytology , Lymphoid Tissue/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , Receptors, Lymphocyte Homing/antagonists & inhibitors , Skin Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...